The shares outstanding are 41.93M, and float is at 41.87M with Short Float at 6.26%.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
VYNE Therapeutics Inc. (NASDAQ: VYNE) is 36.08% higher on its value in year-to-date trading and has touched a low of $4.00 and a high of $23.36 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The VYNE stock was last observed hovering at around $8.54 in the last trading session, with the day’s gains setting it 0.06% off its average median price target of $20.00 for the next 12 months. It is also 78.5% off the consensus price target high of $40.00 offered by 7 analysts, but current levels are 28.33% higher than the price target low of $12.00 for the same period.
Currently trading at $8.60, the stock is -13.88% and 6.50% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.18 million and changing 0.70% at the moment leaves the stock 17.06% off its SMA200. VYNE registered -59.13% loss for a year compared to 6-month gain of 31.90%. The firm has a 50-day simple moving average (SMA 50) of $8.74 and a 200-day simple moving average (SMA200) of $7.21.
The stock witnessed a 18.13% loss in the last 1 month and extending the period to 3 months gives it a 27.98%, and is -19.17% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.13% over the week and 12.18% over the month.
VYNE Therapeutics Inc. (VYNE) has around 180 employees, a market worth around $438.34M and $16.70M in sales. Distance from 52-week low is 115.00% and -63.18% from its 52-week high.
VYNE Therapeutics Inc. (VYNE) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for VYNE Therapeutics Inc. (VYNE) is a “Buy”. 7 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 7 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
VYNE Therapeutics Inc. quarterly earnings per share for the current quarter are estimated at -$0.53 with sales reaching $4.71M over the same period.The EPS is expected to shrink by -30.30% this year.
VYNE Therapeutics Inc. (VYNE) Insider Activity
The most recent transaction is an insider purchase by PERCEPTIVE ADVISORS LLC, the company’s 10% Owner. SEC filings show that PERCEPTIVE ADVISORS LLC bought 4,219,409 shares of the company’s common stock on Jan 28 at a price of $2.37 per share for a total of $10.0 million. Following the purchase, the insider now owns 27.1 million shares.
VYNE Therapeutics Inc. disclosed in a document filed with the SEC on Dec 03 that LEPORE PATRICK G (Director) bought a total of 50,000 shares of the company’s common stock. The trade occurred on Dec 03 and was made at $1.71 per share for $85425.0. Following the transaction, the insider now directly holds 50000.0 shares of the VYNE stock.